May Measurement Month 2022: an analysis of blood pressure screening results from Nigeria

Ganiyu Amusa(Jos University Teaching Hospital), Ayodele B Omotoso(University of Ilorin), James Ayodele Ogunmodede(University of Ilorin), Henry Iheonye(Federal University Lokoja), Augustine N. Odili(University of Abuja), Akinyemi Aje(University College Hospital, Ibadan), Kolawole Wahab(University of Ilorin Teaching Hospital), Gabriele Kerr(Imperial College London), Abiodun Bello(University of Alabama at Birmingham), Neil R Poulter(Imperial College London), Ernest Nwazor(National Institutes of Health), Sani Abubakar(Ahmadu Bello University), Umezurike Hughes Okafor(Enugu State University of Science and Technology), Yekeen Ayodele Ayoola(Gombe State University), P.M. Kolo(University of Ilorin), Wemimo Alaofin(University of Ilorin), Thomas Beaney(Imperial College London)
European Heart Journal Supplements
February 18, 2025
10.1093/eurheartjsupp/suaf067
Cited by 0

Related Papers

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
|The Lancet|2003|3.8k
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
|The Lancet|2005|2.9k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Interpretation of the evidence for the efficacy and safety of statin therapy
|The Lancet|2016|1.8k